Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma

Authors: Claudio Scafoglio, Brendon Villegas, Gihad Abdelhady, Sean T. Bailey, Jie Liu, Aditya S. Shirali, William D. Wallace, Clara E. Magyar, Tristan Grogan, David Elashoff, Tonya C. Walser, Jane Yanagawa, Denise R. Aberle, Jorge R. Barrio, Steven M. Dubinett, David B. Shackelford - Science Translational Medicine 2018 cited by 175

F] fluoro-alpha-d-glucopyranoside (Me4FDG), which specifically detects SGLT activity. Using a combination of immunohistochemistry and Me4FDG PET, we identified high expression and functional activity of SGLT2 in lung premalignancy and early-stage/low-grade LADC. Furthermore, selective targeting of SGLT2 with FDA-approved small-molecule inhibitors, the gliflozins, greatly reduced tumor growth and prolonged survival in autochthonous mouse models and patient-derived xenografts of LADC. Targeting SGLT2 in lung tumors may intercept lung cancer progression at early stages of development by pairing Me4FDG PET imaging with therapy using SGLT2 inhibitors.